 This study found that dolyutegraver, DTG, and integrase inhibitor resulted in improved lipid profiles when compared to ifavarenz, EFV. DTG showed lower levels of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides while maintaining stable body weight and waist circumference. This suggests that DTG may be beneficial for patients with HIV who have a high risk of cardiovascular disease. This article was authored by Safachokokemla, Atabor D. Miesing, Wantin Srybenjalex, and others.